InsidersTradesSigma
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Explore the complete record of transactions filed by Peterson Katharine. Director active across 1 company, notably Acrivon Therapeutics, Inc.. In total, 9 disclosures have been logged. Breakdown: 0 buy · 1 sell. Total volume traded: €175. Activity tracked since 14 May 2024. The latest transaction was filed on 18 August 2026 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
9 条申报中的 9 条
Peterson Katharine is a declarant and Chief Accounting Officer at Acrivon Therapeutics, Inc. She has 8 filings in total. In the 8 most recent sampled filings, all related to Acrivon Therapeutics, Inc., the stated transaction nature is Tax withholding, with individual amounts of EUR 765.3021378003997 on 2024-05-16, EUR 742.2101034030217 on 2024-11-18, EUR 631.0418445135629 on 2024-08-16, EUR 600.9745819180918 on 2025-02-19, EUR 190.6470751749482 on 2025-11-18, and EUR 159.3131443192366 on 2026-02-18. The period covered by these filings runs from 2024-05-16 to 2026-02-18.